Here are the 424B prospectus supplements from Larimar Therapeutics, Inc. (LRMR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LRMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LRMR filings page.
Larimar Therapeutics is offering 20,000,000 shares of its common stock at a public offering price of $5.00 per share. The offering includes an underwriter option to purchase up to an additional 3,000,000 shares. Delivery of the shares is expected on or about February 27, 2026.
The cover page shows underwriting discounts of $0.30 per share and proceeds to the company before expenses of $94,000,000. The offering is being made from a shelf registration on Form S-3 and assumes no exercise of outstanding options; management retains broad discretion over use of proceeds.
Larimar Therapeutics is offering $75.0 million of common stock and associated pre‑funded warrants. The prospectus supplement outlines an at‑the‑market shelf background and an underwritten offering that includes a 30‑day option for up to an additional $11.25 million of common stock.
The company reports unaudited preliminary cash, cash equivalents and marketable securities of $136.9 million as of December 31, 2025. The filing notes FDA Breakthrough Therapy Designation for nomlabofusp and a planned BLA submission targeted for June 2026. The prospectus discloses 80,590,392 shares outstanding as the base for post‑offering calculations and describes usual issuance, dilution, lock‑up and underwriting terms.